Skip to main content
SpringerLink
Log in

Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim of our study was to identify factors which influence survival in patients with disseminated seminoma in the good prognostic group according to IGCCCG, as well as to evaluate the impact of treatment intensification in patients with negative prognostic factors.

Methods

We analyzed the database of the patients with metastatic seminoma who had received treatment at our department from 1986 to 2005. Inclusion criteria were as follows: morphologically verified seminoma; favorable prognosis according to IGCCCG; modern chemotherapy regimen (EP ± bleomycin); AFP level <15 IU/ml; and HCG level <300 mIU/ml. The primary endpoint was overall survival (OS).

Results

With median follow-up 83 months, 5-year OS rate was 91 % in 206 patients. Only three negative prognostic factors were associated with OS: retroperitoneal lymph nodes >5 cm (p < 0.01), pulmonary metastases (p < 0.01) and LDH level ≥2.25×ULN (p = 0.01). In view of the obtained data, we have changed our treatment approach since 2005. In case of any negative prognostic factors, we administered an intensified CT regimen—4BEP or 3BEP + 1EP. Prospective phase of the study included 34 patients with unfavorable prognosis. We observed an increase of 5-year OS rate in the intensified CT group in comparison with the standard CT group in patients with unfavorable prognostic from 85 to 100 %.

Conclusion

Administration of 4 cycles of induction CT (4BEP or 3BEP + 1EP) in patients with metastatic seminoma who have LDH level ≥2.25 ULN, and/or retroperitoneal lymph nodes >5 cm and/or pulmonary metastases results in decreased disease progression rate and significant gain in OS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Beyer J, Albers P, Altena R et al (2012) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 00:1–11. doi:10.1093/annonc/mds579

    Google Scholar 

  • Fizzazi K, Devta R, Caty A et al (2014) A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol 65(2):381–386

    Article  Google Scholar 

  • Fossa SD, Oliver RT, Stenning SP et al (1997) Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 33(9):1380–1387

    Article  CAS  PubMed  Google Scholar 

  • Gholam D, Fizzazi K, Terrier-Lacombe MJ et al (2003) Advanced seminoma—treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease. Cancer 98(4):745–752

    Article  PubMed  Google Scholar 

  • International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603

    Google Scholar 

  • Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of second meeting of the European Germ Cell Cancer Concensus Group (EGCCCG): part II. Eur Urol 53:497–513

    Article  PubMed  Google Scholar 

  • Mencel PJ, Motzer RJ, Mazumdar M et al (1994) Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 12(1):120–126

    CAS  PubMed  Google Scholar 

  • Powles T, Bascoul-Mollevi C, Kramar A et al (2013) Prognostic impact of LDH levels in patients with relapsed/refractory seminoma. J Cancer Res Clin Oncol 139(8):1311–1316

    Article  CAS  PubMed  Google Scholar 

  • Ruther U, Rothe B, Grunert K et al (1994) Role of human chorionic gonadotropin in patients with pure seminoma. Eur Urol 26(2):129–133

    CAS  PubMed  Google Scholar 

  • Weissbach L, Bussar-Maatz R, Löhrs U et al (1999) Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group. Eur Urol 36(6):601–608

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoye Shosse, Moscow, 115478, Russia

    Mikhail Fedyanin, Alexey Tryakin, Anatoly Bulanov, Anna Vybarava, Alexandra Tjulandina, Dzhennet Chekini, Olga Sekhina, August Garin & Sergei Tjulandin

  2. Department of Urologic Oncology, N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

    Konstantin Figurin

Authors
  1. Mikhail Fedyanin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexey Tryakin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anatoly Bulanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Vybarava
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandra Tjulandina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dzhennet Chekini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Olga Sekhina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Konstantin Figurin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. August Garin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sergei Tjulandin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mikhail Fedyanin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fedyanin, M., Tryakin, A., Bulanov, A. et al. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors. J Cancer Res Clin Oncol 141, 1259–1264 (2015). https://doi.org/10.1007/s00432-015-1914-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-015-1914-5

Keywords

Search

Navigation